Chemistry:TTX-030
From HandWiki
| Monoclonal antibody | |
|---|---|
| Type | ? |
| Identifiers | |
| CAS Number | |
TTX-030 is an experimental anti-CD39 monoclonal antibody developed by AbbVie to treat pancreatic cancer.[1][2][3][4]
References
- ↑ "Pipeline". https://www.abbvie.com/science/pipeline.html#ttx-030.
- ↑ Lerner, Alana G.; Kovalenko, Maria; Welch, Megan; Cruz, Tracy dela; Jones, Jeff; Wong, Clifford; Spatola, Bradley; Eberhardt, Meghan et al. (1 July 2019). "Abstract 5012: Targeting CD39 with a first-in-class inhibitory antibody prevents ATP processing and increases T-cell activation". Cancer Research 79 (13_Supplement): 5012. doi:10.1158/1538-7445.AM2019-5012.
- ↑ Spatola, Bradley N.; Lerner, Alana G.; Wong, Clifford; dela Cruz, Tracy; Welch, Megan; Fung, Wanchi; Kovalenko, Maria; Losenkova, Karolina et al. (1 January 2020). "Fully human anti-CD39 antibody potently inhibits ATPase activity in cancer cells via uncompetitive allosteric mechanism". mAbs 12 (1). doi:10.1080/19420862.2020.1838036. PMID 33146056.
- ↑ Wainberg, Zev; Kang, Yoon-Koo; Lee, Keun-Wook; Kim, Seung Tae; Chao, Joseph; Catenacci, Daniel; Oh, Sung Yong; Soares, Heloisa P. et al. (15 June 2022). "Abstract CT015: Safety and efficacy of TTX-030, an anti-CD39 antibody, in combination with chemoimmunotherapy for the first line treatment of locally advanced or metastatic gastric/GEJ cancer". Cancer Research 82 (12_Supplement): CT015. doi:10.1158/1538-7445.AM2022-CT015.
 |  |
